Financial Performance - MercadoLibre's net revenues reached US$6790 million, demonstrating a year-over-year (YoY) growth of 338%[66] - The company's Gross Merchandise Volume (GMV) hit US$153 billion, marking a 372% YoY increase on an FX-Neutral basis[11,68] - Adjusted free cash flow was US$454 million[11,58] - Net income reached US$523 million, representing a 77% margin[11,68] Marketplace Metrics - Unique active buyers increased to 708 million, a 25% YoY growth[11,16] - Items sold totaled 5501 million, reflecting a 306% YoY increase[11,68] - Same & Next Day Shipments increased +28% YoY[23] Fintech Performance - Total Payment Volume (TPV) grew to US$646 billion, a 609% YoY increase on an FX-Neutral basis[11,68] - Fintech monthly active users reached 676 million, a 30% YoY growth[28] - The credit portfolio expanded to US$93 billion, showing a 91% YoY growth[11,31] - Assets Under Management (AUM) increased to US$138 billion, a 109% YoY growth[31,68]

Company Overview - Inspire Medical Systems has an underpenetrated U S market exceeding $10 billion[7,9,26] - The company achieved over $800 million in revenue in 2024, demonstrating a 28% year-over-year growth[7,10] - Inspire therapy has established reimbursement in all 50 U S states, covering over 300 million lives[7,9] - Over 100,000 patients have received Inspire therapy, highlighting a significant first-mover advantage[7,8,9,33] Financial Performance & Growth Strategy - The company projects FY2025 revenue between $900 million and $910 million, representing a 12%-13% growth over FY2024[65] - The gross margin for FY2025 is expected to be between 84% and 86%[65] - Inspire initiated the full launch of the Inspire V system in the U S in May 2025[70,71] - Second quarter revenue reached $217 1 million, an 11% increase year-over-year, with a gross margin of 84%[70] Therapy & Market - Inspire therapy demonstrates a median Apnea-Hypopnea Index (AHI) reduction from 33 0 events/hr at baseline to 10 2 events/hr at 12 months[43] - Inspire patients reported a median Epworth Sleepiness Scale (ESS) score reduction from 11 0 at baseline to 6 0 at the 12-month visit[44] - 91% of patients say Inspire is better than CPAP, and 93% would recommend Inspire to a friend or family member[46]

Financial Performance - The company's quarterly net revenue reached $317.2 million[25] - On a constant currency basis, net revenue was $313.1 million for the second quarter[25] - Adjusted EBITDA was $33.9 million with an Adjusted EBITDA Margin of 10.7% for the second quarter[25] - Net income was $21.1 million for the second quarter, with an adjusted net income of $18.1 million[25] - Diluted earnings per share were $0.99 for the second quarter, and adjusted diluted earnings per share were $0.85[25] Segment Performance - Executive Search saw a 13.4% year-over-year revenue growth in the second quarter[32] - On-Demand Talent experienced a 14.3% year-over-year revenue growth in the second quarter[32] - Heidrick Consulting achieved a 16.6% year-over-year revenue growth for the second quarter[32] Balance Sheet - The company maintains a strong and flexible balance sheet with zero debt[16] - Cash provided by operating activities was $68.6 million as of June 30, 2025[57]

Second-Quarter 2025 Earnings Call Presentation Reported August 4, 2025 © 2025 BWX Technologies. Inc. All Rights Reserved. The products and services described herein are provided by subsidiaries of BWX Technologies, Inc. Forward-Looking Statements Disclaimer Our Purpose: We employ nuclear technology to solve some of the world's most important problems Our Mission: We provide safe and effective nuclear solutions for global security, clean energy, environmental remediation, nuclear medicine, and space explorat ...

Financial Performance Highlights - Paymentus achieved a revenue of $280.1 million in Q2 2025, representing a year-over-year (YoY) growth of 41.9%[10, 14] - Contribution profit reached $93.5 million in Q2 2025, a 22.3% increase compared to Q2 2024[10, 14] - Adjusted EBITDA for Q2 2025 was $31.7 million, showing a 40.7% YoY growth[10, 14] - Net income increased by 44.8% to $19.3 million, with EPS rising by 50% to $0.15[14] Additional Financial Data - Cash and cash equivalents increased to $270.0 million in Q2 2025, an 8.2% increase from Q1 2025[17] - Free cash flow was $22.5 million in Q2 2025, a decrease of 45.3% compared to Q1 2025[17] Q3 and FY 2025 Financial Guidance - The company projects Q3 2025 revenue between $278 million and $282 million, contribution profit between $92 million and $94 million, and adjusted EBITDA between $30 million and $32 million[19] - Revised FY 2025 revenue guidance is $1.123 billion to $1.132 billion, a 4.2% increase from the prior guidance midpoint[19] - Revised FY 2025 contribution profit guidance is $369 million to $373 million, a 1.4% increase from the prior guidance midpoint[19] - Revised FY 2025 adjusted EBITDA guidance is $123 million to $127 million, a 4.2% increase from the prior guidance midpoint[19]

Company Overview - Navitas Semiconductor is positioned as a pure-play next-generation power semiconductor company, focusing on GaN and SiC technologies[8] - The company has shipped over 300 million GaN power ICs without silicon power MOSFETs[9] - Navitas has a strong IP portfolio with over 300 patents issued or pending related to GaN and SiC[9, 45] - Navitas' annual revenue has grown significantly, reaching $84 million in 2024[9] Technology and Market Disruption - GaN and SiC technologies are replacing silicon in next-generation power applications, offering up to 20x faster switching and up to 3x higher power density[12] - GaN-based systems can achieve up to 40% energy savings and up to 25% lower system cost compared to Si-based systems[12] - Navitas has enabled the GaN mobile charger market, achieving up to 3x faster charging in half the size and weight[14] AI Data Center Opportunity - AI is driving a dramatic increase in power demands, requiring a 100x increase in server rack power[18, 20] - The transition to 800V data centers is expected to increase the power semiconductor TAM to $2.6 billion per year by 2030, presenting a significant opportunity for GaN and SiC[32] - The adoption of 800V data centers is projected to grow from 0% in 2025 to 80% of total AI data centers by 2030[38] - The power semi TAM for 800V data centers is estimated to reach $2.564 billion in 2030[38] - GaN and SiC technologies can capture a significant percentage of the total $3 billion per year AI data center opportunity (48V + 800V)[42]

Q2 2025 Highlights - Adjusted EPS was $016[20] - The Rule of 40 score was 94%[22] - Adjusted free cash flow was $569 million, with a 57% margin[22] - Adjusted operating income was $464 million, with a 46% margin[22] - The company closed 157 deals of at least $1 million, 66 deals of at least $5 million, and 42 deals of at least $10 million[22] Revenue Growth - Total revenue grew by 48% year-over-year (Y/Y) and 14% quarter-over-quarter (Q/Q) to $1004 billion[22] - Excluding Strategic Commercial Contracts, total revenue grew by 49% Y/Y and 14% Q/Q[22] - US revenue grew by 68% Y/Y and 17% Q/Q to $733 million[22] - US commercial revenue grew by 93% Y/Y and 20% Q/Q to $306 million[22] - US government revenue grew by 53% Y/Y and 14% Q/Q to $426 million[22] US Commercial Performance - US commercial remaining deal value (RDV) grew by 145% Y/Y and 20% Q/Q to $28 billion[22] - US commercial total contract value (TCV) reached a record high of $843 million, representing a 222% Y/Y increase[22] - US Commercial Customer Count grew 64% Y/Y[58] Financial Position - The company ended Q2 2025 with $60 billion in cash, cash equivalents, and US Treasury securities and no debt[90] Q3 and FY 2025 Outlook - For Q3 2025, the company expects revenue between $1083 billion and $1087 billion and adjusted income from operations between $493 million and $497 million[94] - For FY 2025, the company expects revenue between $4142 billion and $4150 billion, US commercial revenue in excess of $1302 billion (at least 85% growth), adjusted income from operations between $1912 billion and $1920 billion, and adjusted free cash flow between $18 billion and $20 billion[93]

Financial Performance - PRA Group achieved net income of $42 million in Q2 2025, or $13 million excluding the after-tax gain from the RCB sale in Brazil[24] - The company's revenues increased by 1% to $288 million in Q2 2025[25] - Adjusted EBITDA grew by 16% year-over-year[29] Portfolio and Investments - The company's purchase price multiples (PPMs) have improved, with 1H 2025 PPMs at 1.82x for Purchases and 2.14x for ERC[16] - Total cash collections increased by 13%[19] - Portfolio income is growing, with a 14% increase in Q1 2025 and a 20% increase in Q2 2025[22] Capital Structure and Strategy - PRA Group has no debt maturities until 2027[12] - The company repurchased $10 million of shares during the quarter[32, 34] - The company has $841 million available under its credit facilities as of June 30, 2025[34]

Financial Performance - Q2 2025 revenue reached $106 million[11] - The company reported an operating loss of $1.1 million[15] - Earnings per share stood at $0.22[19] - Revenue per active earning coach (AEC) was $4,630[13, 14] - As of June 30, 2025, cash and investments totaled $163 million[6, 21, 22] Coach Network and Productivity - The company has 22,800 active earning coaches[20] - Revenue per active earning coach declined 6.9% year-over-year but increased sequentially for the second consecutive quarter[8] - New coach productivity exceeded the same period last year[8] - 60% of coaches have had at least one client on GLP-1 medications[30, 70] Strategic Initiatives - The company is focusing on science-driven innovation and offer evolution[23, 65] - The Premier+ program streamlines pricing and processes to improve retention and aid recruitment[25, 48, 51] - The OPTAVIA EDGE program is designed to drive coach productivity, client acquisition, and leadership development[52, 71] Market and Health Focus - The company is addressing the rising metabolic health challenge, with 9 out of 10 U S adults being metabolically unhealthy[31, 69] - The OPTAVIA 5&1 Plan has been shown to impact key drivers of metabolic health, retaining 98% of lean mass in a clinical trial[38, 40] Q3 2025 Guidance - The company projects Q3 2025 revenue between $70 million and $90 million[75] - Q3 2025 loss/earnings per share is expected to be between ($0.60) and $0.00[75]

Investor Presentation Q2 2025 Update 1 Certain statements in this presentation may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Offerpad's future financial or operating performance. For example, statements regarding Offerpad's financial outlook, including homes sold, revenue and Adjusted EBITDA, for the first quarter of 2025, and expectations regarding market conditions, st ...